Ironwood Pharmaceuticals Q1 2021 Earnings Report
Key Takeaways
Ironwood Pharmaceuticals reported a strong start to the year with U.S. LINZESS net sales increasing by 12% year-over-year to $215 million. Total revenue reached $89 million, driven by U.S. LINZESS collaboration revenue. The company ended the quarter with $438 million in cash and cash equivalents and is maintaining its full-year 2021 financial guidance.
LINZESS U.S. net sales reached $215 million, a 12% increase year-over-year.
Total revenue was $89 million, up 11% year-over-year, primarily due to U.S. LINZESS collaboration revenue of $86 million.
GAAP net income was $40 million, and adjusted EBITDA was $46 million.
The company ended Q1 2021 with $438 million in cash and cash equivalents.
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals
Forward Guidance
Ironwood is maintaining its full year 2021 financial guidance.